Well Hectort you don't mention any of the patents granted, the stages of the clinical developments already achieved and that orphan status has been granted on 2 continents for certain of its' products.
From a clinical/scientific perspective they have announced that they're studying ways to achieve production on SM6 and I've no doubt they're also working on other developments currently in their pipeline. The Chinese deal has placed the company in an earning position which is great. What many people don't realize about China is the numbers of people they have. In Australia to solve a problem a company might throw 1 or 2 PHds at it, in Europe and America perhaps 5 or 10 however in China they'll throw 100 or 200 PHds at it.
Also I think getting out of the CAR-T program is a good move as it focuses the company and it apprears that just about every bio on earth is looking at CAR-T things.
It could also just be that you write so elegantly negative because you're buying whatever you can get you hands on at these prices??
PAB Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
